Cowen initiated coverage on shares of ALX Oncology (NASDAQ:INZY) in a research report report published on Tuesday morning, BenzingaRatingsTable reports. The firm issued an outperform rating on the stock.
Shares of NASDAQ INZY opened at $28.50 on Tuesday. ALX Oncology has a 52 week low of $16.10 and a 52 week high of $31.27.
In other ALX Oncology news, major shareholder Longitude Capital Partners Iii bought 625,000 shares of ALX Oncology stock in a transaction dated Tuesday, July 28th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $10,000,000.00. Also, Director Robert Lorne Hopfner bought 187,500 shares of ALX Oncology stock in a transaction dated Tuesday, July 28th. The stock was acquired at an average price of $16.00 per share, with a total value of $3,000,000.00.
About ALX Oncology
Inozyme Pharma, Inc, a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis.
Read More: Cryptocurrencies
Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.